Brooks Laboratories Valuation

Is BROOKS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BROOKS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BROOKS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BROOKS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BROOKS?

Key metric: As BROOKS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BROOKS. This is calculated by dividing BROOKS's market cap by their current revenue.
What is BROOKS's PS Ratio?
PS Ratio	4.7x
Sales	₹781.93m
Market Cap	₹3.71b

BROOKS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.9x
Enterprise Value/EBITDA	104.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BROOKS's PS Ratio compare to its peers?

The above table shows the PS ratio for BROOKS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.7x
526853 Bilcare	0.2x	n/a	₹1.3b
544184 Borosil Scientific	3.8x	n/a	₹16.1b
524394 Vimta Labs	5x	n/a	₹16.5b
TARSONS Tarsons Products	5.7x	14.5%	₹20.9b
BROOKS Brooks Laboratories	4.7x	n/a	₹3.7b

Price-To-Sales vs Peers: BROOKS is expensive based on its Price-To-Sales Ratio (4.7x) compared to the peer average (3.7x).

Price to Sales Ratio vs Industry

How does BROOKS's PS Ratio compare vs other companies in the Asian Life Sciences Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BROOKS is expensive based on its Price-To-Sales Ratio (4.7x) compared to the Asian Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is BROOKS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BROOKS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BROOKS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

-0.09%

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

14.0%

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

6.1%